Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2784 • 2015 ACR/ARHP Annual Meeting
Faecal Levels of Calprotectin Are Increased in Patients with Primary Sjögren’s Syndrome and Correlates with Disease Activity
Thomas Mandl¹, Bodil Ohlsson² and Kristofer Andreasson³, ¹Dept of Rheumatology, Skåne University Hospital Malmö, Lund University, Malmo, Sweden, ²Dept of Internal Medicine, Skane University Hospital Malmo, Lund University, Sweden, Malmo, Sweden, ³Dept of Rheumatology, Skane University Hospital Lund, Lund University, Sweden, Lund, Sweden
Background/Purpose: FC is a validated biomarker differentiating inflammatory bowel disease from irritable bowel syndrome. We have evaluated faecal levels of calprotectin (FC) in patients with…
Abstract Number: 3204 • 2015 ACR/ARHP Annual Meeting
Hypoechoic Lesions on Parotid Gland Ultrasound Are a Surrogate Marker of Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy in Sjögren’s Syndrome
Thomas Grader-Beck¹, Joel Fradin², Jean Kim³, Esen Akpek⁴, Brendan Antiochos⁵, Julius Birnbaum⁶ and Alan N. Baer⁷, ¹Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ³Otolaryngology, Head & Neck Surgery, Johns Hopkins University, Baltimore, MD, ⁴Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine-Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To determine whether hypoechoic lesions on parotid gland ultrasound can serve as a surrogate marker for a focus score ≥1 on minor salivary gland…
Abstract Number: 629 • 2015 ACR/ARHP Annual Meeting
Salivary Gland Ultrasonography As an Useful Tool to Distinguish Patients with Sjögren’s Syndrome at Risk for Non-Hodgkin’s Lymphoma Development
Chiara Baldini¹, Nicoletta Luciano¹, Francesco Ferro¹, Chiara Stagnaro¹, Daniela Martini¹, Marta Mosca² and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²University of Pisa, Pisa, Italy
Background/Purpose: Salivary gland ultrasonography has been proposed as a promising novel tool for the diagnosis of primary Sjögren’s syndrome (SS). An increasing number of studies…
Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting
Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome
Saba Nayar¹, Joana Campos¹, Christopher Buckley¹, Rodger Allen², W.A. Fahy², Andrew Payne² and Francesca Barone¹, ¹University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, ²UCB Pharma, Slough, United Kingdom
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
Abstract Number: 2785 • 2015 ACR/ARHP Annual Meeting
Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome
Yoshiyuki Arinuma^1,2, Yuko Sakuma³, Eisuke Ogawa², Tatsuhiko Wada⁴, Tatsuo Nagai², Sumiaki Tanaka² and Shunsei Hirohata², ¹Center for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁴Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Sjögren syndrome (SjS) is one of the autoimmune disease characterized by the production of autoantibodies. Patients with SjS frequently observe psychiatric manifestation such as…
Abstract Number: 3205 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept or Rituximab Targets T Follicular Helper Cells in Patients with Primary Sjogren s Syndrome
Gwenny M. Verstappen¹, Petra M. Meiners², Odilia B.J. Corneth³, Rudi W. Hendriks³, Arjan Vissink⁴, Frans G.M. Kroese⁵ and Hendrika Bootsma⁵, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands, ⁴Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: T cell-dependent B cell hyperactivity is a characteristic pathogenetic feature of primary Sjögren’s syndrome (pSS). This is illustrated by the finding that treatment of…
Abstract Number: 631 • 2015 ACR/ARHP Annual Meeting
Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients
Soledad Retamozo¹, Pilar Brito-Zerón¹, Albert Bové², Hoda Gheitasi², Courtney Grant³, Daphne Superville⁴, Belchin Kostov⁵, Antoni Sisó-Almirall⁵, Llucia Alós⁶ and Manuel Ramos-Casals¹, ¹Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, ²Department of Autoimmune Diseases, IDIBAPS, Hospital Clínic, Barcelona, Spain, ³University of Glasgow, Glasgow, United Kingdom, ⁴Massachusetts Institute of Technology (MIT), Cambridge, MA, ⁵Primary Care Research Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Primary Care Centre Les Corts, CAPSBE, Barcelona, Spain, ⁶Department of Pathology, Hospital Clínic, Barcelona, Spain
Background/Purpose: Sicca syndrome is a clinical presentation that is common for several systemic diseases that may infiltrate the exocrine glands. The most frequent disease is…
Abstract Number: 1055 • 2015 ACR/ARHP Annual Meeting
Expansions of Salivary Gland CD4+ T Cells from Sjögren’s Syndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures of Disease
Michelle L. Joachims¹, Kerry M. Leehan^2,3, Christina M. Lawrence³, Astrid Rasmussen³, Lida Radfar⁴, David M. Lewis⁵, Glen D Houston⁶, Kiely Grundahl³, Donald U. Stone^7,8, Kimberly Hefner⁹, R. Hal Scofield^2,10,11, Kathy L. Sivils^2,3, Linda F. Thompson¹² and A. Darise Farris^1,2, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁵College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Heartland Pathology, Oklahoma City, OK, ⁷Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Hefner Eye Care and Optical Center, Oklahoma City, OK, ¹⁰College of Medicine, Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: CD4+ T cells predominate in salivary gland (SG) focal lymphocytic infiltrates in primary Sjögren’s syndrome (pSS). However, their antigen specificity, degree of clonal…
Abstract Number: 2787 • 2015 ACR/ARHP Annual Meeting
Expression of Interferons Lambda in Salivary Glands of Patients with Sjögren’s Syndrome
Eirini Apostolou¹, Efstathia K. Kapsogeorgou¹, Orsia D. Konsta¹, Maria Ioanna Saridaki², Evangelos Andreakos² and Athanasios G. Tzioufas¹, ¹Pathophysiology, Faculty of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece, ²Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, Athens, Greece
Background/Purpose: Type I and II interferons (IFNs) have been implicated in the pathophysiology of Sjögren’s Syndrome (SS). Recently a new family of IFNs, namely type…
Abstract Number: 2806 • 2014 ACR/ARHP Annual Meeting
Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls
Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose : IgG4-related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4-positive plasma cells and T cells into various organs.…
Abstract Number: 2531 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon², Karn Wijarnpreecha³, Wisit Cheungpasitporn², Praveen Ratanasrimetha⁴ and Promporn Suksaranjit⁵, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Venous Thromboembolism in Patients with Sjogren's Syndrome: A Systematic Review and Meta-analysisBackground/Purpose: Venous thromboembolism (VTE) is a common medical problem with a significant…
Abstract Number: 521 • 2014 ACR/ARHP Annual Meeting
CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren ’s Syndrome Patients
Gaetane Nocturne¹, Olivier Fogel², Philippe Dieude³, Jean Jacques Dubost⁴, Anne-Laure Fauchais⁵, Vincent Goeb⁶, Eric Hachulla⁷, Claire Larroche⁸, Véronique Le Guern⁹, Jacques Morel¹⁰, Aleth Perdriger¹¹, Xavier Puéchal¹², Stephanie Rist Bouillon¹³, Valerie Devauchelle¹⁴, Damien Sène¹⁵, O Vittecoq¹⁶, Corinne Miceli-Richard¹⁷, Jacques Gottenberg¹⁸ and Xavier Mariette¹⁹, ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁴Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rhumatology Department, University Hospital, AMIENS, France, ⁷Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁸Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ⁹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹¹Rhumatologie, Rennes, France, ¹²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹³Rhumatologie, Hopital La Source, La Source, France, ¹⁴Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ¹⁵Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁶Rouen University Hospital & Inserm U905, Rouen, France, ¹⁷Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ¹⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications associated with pSS. It affects 5-10% of the patients. Definition of predictive…
Abstract Number: 2725 • 2014 ACR/ARHP Annual Meeting
Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren’s Syndrome Patients
S.L.M. Blokland^1,2, M.R. Hillen^1,2, A.a. Kruize², A. Kislat³, S. Meller³, B. Homey³, G.M. Smithson⁴, J. Zalevsky⁵, T.R.D.J. Radstake² and J.a.G. van Roon², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Dermatology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany, ⁴Takeda Pharmaceuticals International, Chicago, IL, ⁵Takeda California, San Diego, CA
Background/Purpose In primary Sjögren’s syndrome (pSS) B cell activation and autoantibody secretion are hallmark immunopathological features. Specific lymphoid organization (including germinal centers) is associated with…
Abstract Number: 2174 • 2014 ACR/ARHP Annual Meeting
MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren’s Syndrome
Adrienne Gauna¹, Jun-O Jin^2,3, Qing Yu², Carol Stewart¹ and Seunghee Cha¹, ¹Oral and Maxillofacial Diagnostic Sciences, University of Florida, Gainesville, FL, ²Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, MA, ³Shanghai Public Health Clinical Center, Fudan University Shanghai Medical College, Shanghai, China
Background/Purpose: Sjögren’s syndrome (SS) causes severe dry mouth and eyes. The presence of immune cell infiltration in the salivary (SG) and lacrimal glands suggests a…
Abstract Number: 520 • 2014 ACR/ARHP Annual Meeting
Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren’s Syndrome Patients (pSS)
Gaetane Nocturne¹, Olivier Fogel², Joanne Nititham³, Kimberly E. Taylor⁴, Philippe Dieude⁵, Jean Jacques Dubost⁶, Anne-Laure Fauchais⁷, Vincent Goëb⁸, Eric Hachulla⁹, Claire Larroche¹⁰, Véronique Le Guern¹¹, Jacques Morel¹², Aleth Perdriger¹³, Xavier Puéchal¹⁴, Stephanie Rist Bouillon¹⁵, Alain Saraux¹⁶, Damien Sène¹⁷, Olivier Vittecoq¹⁸, Lindsey A. Criswell¹⁹, Corinne Miceli-Richard²⁰, Jacques Gottenberg²¹ and Xavier Mariette²², ¹INSERM U1012, Paris sud university, Le Kremlin Bicetre, France, ²INSERM U1012, Paris sud university, Le Kremlin Bicêtre, France, ³University of California San Francisco, 374 Parnassus Avenue, San Francisco, CA, ⁴Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Rhumatologie, Hopital Bichat Claude Bernard, Paris, France, ⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁸Rheumatology, Amiens University Hospital, Amiens, France, ⁹Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ¹⁰Internal Medicine, Avicenne Hospital,, Assistance Publique des Hôpitaux de Paris,, Bobigny, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹³Rhumatologie, Rennes, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁵Rhumatologie, Hopital La Source, La Source, France, ¹⁶CHU Brest and EA 2216, UBO, Brest, France, ¹⁷Hopital Lariboisière, service de Médecine Interne, Paris, France, ¹⁸Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹⁹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²⁰Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ²¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²²rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose: Development of non-Hodgkin lymphoma (NHL) is one of the most severe complications of pSS. It occurs in 5-10% of the patients. A more accurate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].